Literature DB >> 2199130

Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

K Lauritsen1, L S Laursen, J Rask-Madsen.   

Abstract

Part I of this article, which appeared in the previous issue of the Journal, covered the following agents: histamine H2-receptor antagonists (cimetidine, ranitidine, famotidine, nizatidine); muscarinic-M1-receptor antagonists (pirenzepine); proton pump inhibitors (omeprazole); site-protective agents (colloidal bismuth subcitrate, sucralfate); antacids and prostaglandin analogues; antiemetics and prokinetics (metoclopramide, domperidone, cisapride); and antispasmodics. In Part II, we consider the anti-inflammatory salicylates, nonspecific antidiarrhoeal agents, laxatives and cathartics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2199130     DOI: 10.2165/00003088-199019020-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  645 in total

1.  Kinetics of the binding of salicylazosulfapyridine to human serum albumin.

Authors:  J A Jansen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1977-11

2.  Enprostil, in contrast to cimetidine, does not inhibit propranolol metabolism.

Authors:  C S Reilly; J Biollaz; R P Koshakji; A J Wood
Journal:  Clin Pharmacol Ther       Date:  1986-07       Impact factor: 6.875

3.  Influence of cimetidine and ranitidine on ethanol pharmacokinetics.

Authors:  L K Webster; D B Jones; R A Smallwood
Journal:  Aust N Z J Med       Date:  1985-06

4.  Lack of effect of nizatidine on hepatic drug metabolism in man.

Authors:  J W Secor; K V Speeg; C G Meredith; R F Johnson; P Snowdy; S Schenker
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

5.  Placental and mammary transfer of sulphasalazine.

Authors:  A K Khan; S C Truelove
Journal:  Br Med J       Date:  1979-12-15

Review 6.  Diazepam-cimetidine drug interaction: a clinically significant effect.

Authors:  R L Ruffalo; J F Thompson; J L Segal
Journal:  South Med J       Date:  1981-09       Impact factor: 0.954

7.  Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

Authors:  O Haagen Nielsen; S Bondesen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

8.  The influence of cimetidine on the pharmacokinetics of 5-fluorouracil.

Authors:  V J Harvey; M L Slevin; M R Dilloway; P I Clark; A Johnston; A F Lant
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

9.  Effects of cimetidine on caffeine disposition in smokers and nonsmokers.

Authors:  D C May; C H Jarboe; A B VanBakel; W M Williams
Journal:  Clin Pharmacol Ther       Date:  1982-05       Impact factor: 6.875

10.  Effect of sucralfate on the bioavailability of cimetidine.

Authors:  H Albin; G Vincon; M C Lalague; P Couzigou; M Amouretti
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more
  13 in total

Review 1.  Neonatal exposure to drugs in breast milk.

Authors:  Patrick J McNamara; Maggie Abbassi
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

2.  Design and evaluation of a novel matrix type multiple units as biphasic gastroretentive drug delivery systems.

Authors:  Meka Lingam; Thadisetty Ashok; Vobalaboina Venkateswarlu; Yamsani Madhusudan Rao
Journal:  AAPS PharmSciTech       Date:  2008-12-31       Impact factor: 3.246

Review 3.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

4.  Relationship between loperamide-induced sedative effect and digoxin pharmacokinetics in healthy Japanese subjects.

Authors:  Michiya Kobayashi; Hiroshi Saitoh; Michiko Yamaguchi; Takeshi Saito; Hiroyoshi Fujita; Manabu Suno; Kazuo Matsubara; Bruce J Aungst
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

Review 5.  Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.

Authors:  A N Wadworth; A Fitton
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

Review 6.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

7.  Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. A possible diarrhogenic factor?

Authors:  C Scheurlen; H Allgayer; W Kruis; E Erdmann; T Sauerbruch
Journal:  Clin Investig       Date:  1993-04

Review 8.  New developments in the pharmacotherapy of inflammatory bowel disease.

Authors:  J W Harting
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

9.  Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats.

Authors:  N Bodor; W M Wu; T Murakami; S Engel
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

10.  Floating granules of ranitidine hydrochloride-gelucire 43/01: formulation optimization using factorial design.

Authors:  Dasharath M Patel; Natavarlal M Patel; Viral F Patel; Darshini A Bhatt
Journal:  AAPS PharmSciTech       Date:  2007-04-13       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.